oru.sePublikationer
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
The European Gonococcal Antimicrobial Surveillance Programme (Euro-GASP)-a sentinel approach in the European Union (EU)/European Economic Area (EEA)
European Ctr Dis Prevent & Control, SE-17183 Stockholm, Sweden..
Publ Hlth England, London, England..ORCID iD: 0000-0002-6707-6910
Orebro University Hospital. Swedish Reference Lab Pathogen Neisseria, Orebro, Sweden.
Statens Serum Inst, Dept Bacteriol, DK-2300 Copenhagen, Denmark..
Show others and affiliations
2013 (English)In: Sexually Transmitted Infections, ISSN 1368-4973, E-ISSN 1472-3263, Vol. 89, no 4, 16-18 p.Article in journal (Refereed) Published
Abstract [en]

Antimicrobial resistance in Neisseria gonorrhoeae is monitored in the European Union/European Economic Area through the European Gonococcal Antimicrobial Surveillance Programme (Euro-GASP) coordinated by the European Centre for Disease Prevention and Control. Euro-GASP includes a sentinel surveillance programme which aims to detect in a timely manner changes in resistance patterns and inform treatment guidelines. The programme aims to test a representative number of isolates from each European Union/European Economic Area member state per year for a range of therapeutically relevant antimicrobials through a biannual hybrid centralised/decentralised system. Testing is supported by an External Quality Assurance programme and a laboratory training programme. Participation in the programme has increased to 21 countries in 2012. Euro-GASP has been able to detect the rapid spread of isolates with decreased susceptibility to cefixime across Europe in 2010 and 2011. Results from the programme have informed changes in European treatment guidelines for gonorrhoea and led to the development of the 'Response plan to control and manage the threat of multidrug resistant gonorrhoea in Europe'. Future challenges for Euro-GASP include supporting countries to participate in Euro-GASP through decentralised testing, improving timeliness and epidemiological data quality, and increasing participation from Eastern Europe.

Place, publisher, year, edition, pages
BMJ Publishing Group Ltd, 2013. Vol. 89, no 4, 16-18 p.
Keyword [en]
antimicrobial treatment, Gonorrhoea, antimicrobial resistance surveillance, European Union (EU), European Economic Area (EEA), Neisseria gonorrhoeae
National Category
Infectious Medicine
Identifiers
URN: urn:nbn:se:oru:diva-56757DOI: 10.1136/sextrans-2013-051117ISI: 000333907100005PubMedID: 24243874OAI: oai:DiVA.org:oru-56757DiVA: diva2:1084001
Available from: 2017-03-23 Created: 2017-03-23 Last updated: 2017-03-23Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Cole, MichelleUnemo, Magnus
By organisation
Orebro University Hospital
In the same journal
Sexually Transmitted Infections
Infectious Medicine

Search outside of DiVA

GoogleGoogle Scholar

Altmetric score

Total: 2 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf